525 related articles for article (PubMed ID: 33421620)
1. CRISPR/Cas mediated epigenome editing for cancer therapy.
Ansari I; Chaturvedi A; Chitkara D; Singh S
Semin Cancer Biol; 2022 Aug; 83():570-583. PubMed ID: 33421620
[TBL] [Abstract][Full Text] [Related]
2. CRISPR-mediated modification of DNA methylation pattern in the new era of cancer therapy.
Maroufi F; Maali A; Abdollahpour-Alitappeh M; Ahmadi MH; Azad M
Epigenomics; 2020 Oct; 12(20):1845-1859. PubMed ID: 33185489
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9 in epigenetics studies of health and disease.
Sar P; Dalai S
Prog Mol Biol Transl Sci; 2021; 181():309-343. PubMed ID: 34127198
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
Tadić V; Josipović G; Zoldoš V; Vojta A
Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
[TBL] [Abstract][Full Text] [Related]
5. Novel Approaches to Epigenetic Therapies: From Drug Combinations to Epigenetic Editing.
Majchrzak-Celińska A; Warych A; Szoszkiewicz M
Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33572577
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic editing: Dissecting chromatin function in context.
Policarpi C; Dabin J; Hackett JA
Bioessays; 2021 May; 43(5):e2000316. PubMed ID: 33724509
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas-Based Epigenome Editing: Advances, Applications, and Clinical Utility.
Goell JH; Hilton IB
Trends Biotechnol; 2021 Jul; 39(7):678-691. PubMed ID: 33972106
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9 Epigenome Editing Potential for Rare Imprinting Diseases: A Review.
Syding LA; Nickl P; Kasparek P; Sedlacek R
Cells; 2020 Apr; 9(4):. PubMed ID: 32316223
[TBL] [Abstract][Full Text] [Related]
9. A Review on CRISPR-mediated Epigenome Editing: A Future Directive for Therapeutic Management of Cancer.
Chakravarti R; Lenka SK; Gautam A; Singh R; Ravichandiran V; Roy S; Ghosh D
Curr Drug Targets; 2022; 23(8):836-853. PubMed ID: 35078394
[TBL] [Abstract][Full Text] [Related]
10. Editing the Epigenome to Tackle Brain Disorders.
Liu XS; Jaenisch R
Trends Neurosci; 2019 Dec; 42(12):861-870. PubMed ID: 31706628
[TBL] [Abstract][Full Text] [Related]
11. Editing the Epigenome: Reshaping the Genomic Landscape.
Holtzman L; Gersbach CA
Annu Rev Genomics Hum Genet; 2018 Aug; 19():43-71. PubMed ID: 29852072
[TBL] [Abstract][Full Text] [Related]
12. Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells.
Okada M; Kanamori M; Someya K; Nakatsukasa H; Yoshimura A
Epigenetics Chromatin; 2017; 10():24. PubMed ID: 28503202
[TBL] [Abstract][Full Text] [Related]
13. Advances of epigenetic editing.
Gjaltema RAF; Rots MG
Curr Opin Chem Biol; 2020 Aug; 57():75-81. PubMed ID: 32619853
[TBL] [Abstract][Full Text] [Related]
14. In vivo epigenome editing and transcriptional modulation using CRISPR technology.
Lau CH; Suh Y
Transgenic Res; 2018 Dec; 27(6):489-509. PubMed ID: 30284145
[TBL] [Abstract][Full Text] [Related]
15. Targeting cancer epigenetics with CRISPR-dCAS9: Principles and prospects.
Rahman MM; Tollefsbol TO
Methods; 2021 Mar; 187():77-91. PubMed ID: 32315755
[TBL] [Abstract][Full Text] [Related]
16. Harnessing CRISPR-Cas9 for Epigenetic Engineering.
Guerra-Resendez RS; Hilton IB
Methods Mol Biol; 2022; 2518():237-251. PubMed ID: 35666449
[TBL] [Abstract][Full Text] [Related]
17. A review on CRISPR/Cas-based epigenetic regulation in plants.
Jogam P; Sandhya D; Alok A; Peddaboina V; Allini VR; Zhang B
Int J Biol Macromol; 2022 Oct; 219():1261-1271. PubMed ID: 36057300
[TBL] [Abstract][Full Text] [Related]
18. Epigenome editing in cancer: Advances and challenges for potential therapeutic options.
Lee SW; Frankston CM; Kim J
Int Rev Cell Mol Biol; 2024; 383():191-230. PubMed ID: 38359969
[TBL] [Abstract][Full Text] [Related]
19. Development of Toolboxes for Precision Genome/Epigenome Editing and Imaging of Epigenetics.
Nomura W
Chem Rec; 2018 Dec; 18(12):1717-1726. PubMed ID: 30066981
[TBL] [Abstract][Full Text] [Related]
20. Epigenome editing by CRISPR/Cas9 in clinical settings: possibilities and challenges.
Pei WD; Zhang Y; Yin TL; Yu Y
Brief Funct Genomics; 2020 May; 19(3):215-228. PubMed ID: 31819946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
